Abstract
Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1167-1173 |
| Number of pages | 7 |
| Journal | Clinical Cancer Research |
| Volume | 11 |
| Issue number | 3 |
| State | Published - Feb 1 2005 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. / Tokumo, Masaki; Toyooka, Shinichi; Kiura, Katsuyuki; Shigematsu, Hisayuki; Tomii, Kunitoshi; Aoe, Motoi; Ichimura, Kouichi; Tsuda, Toshihide; Yano, Masaaki; Tsukuda, Kazunori; Tabata, Masahiro; Ueoka, Hiroshi; Tanimoto, Mitsune; Date, Hiroshi; Gazdar, Adi F.; Shimizu, Nobuyoshi.
In: Clinical Cancer Research, Vol. 11, No. 3, 01.02.2005, p. 1167-1173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers
AU - Tokumo, Masaki
AU - Toyooka, Shinichi
AU - Kiura, Katsuyuki
AU - Shigematsu, Hisayuki
AU - Tomii, Kunitoshi
AU - Aoe, Motoi
AU - Ichimura, Kouichi
AU - Tsuda, Toshihide
AU - Yano, Masaaki
AU - Tsukuda, Kazunori
AU - Tabata, Masahiro
AU - Ueoka, Hiroshi
AU - Tanimoto, Mitsune
AU - Date, Hiroshi
AU - Gazdar, Adi F.
AU - Shimizu, Nobuyoshi
PY - 2005/2/1
Y1 - 2005/2/1
N2 - Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.
AB - Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=19944433797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944433797&partnerID=8YFLogxK
M3 - Article
C2 - 15709185
AN - SCOPUS:19944433797
VL - 11
SP - 1167
EP - 1173
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 3
ER -